Who
Shankar Musunuri
Chief Executive Officer
Company insider
Files Form 4 as: Chief Executive Officer, Ocugen.
In numbers
- Trades disclosed
- 70
- Buys
- 2
- Sells
- 18
- Bought
- $158K
- Sold
- $11.9M
- Companies
- 1
- Companies where not an officer
- 0
- First trade
- 11 Dec 2019
- Last trade
- 9 Oct 2026
- Last filed
- 13 Oct 2026
Companies traded
Activity over time
1 Nov 2024 – 1 Oct 2026
Buys above the line, sells below, each month.
Every trade
| Traded | Company | What | Amount | |
|---|---|---|---|---|
| 9 Oct 2026filed 13 Oct 2026 | OCGN OcugenBiotechnology | SEC FORM 4 Sold | $445K468,727 at $0.95 | filing |
| 9 Oct 2026filed 13 Oct 2026 | OCGN OcugenBiotechnology | SEC FORM 4 Sold | $54K57,264 at $0.95 | filing |
| 9 Sep 2026filed 11 Sep 2026 | OCGN OcugenBiotechnology | SEC FORM 4 Sold | $525K468,727 at $1.12 | filing |
| 9 Sep 2026filed 11 Sep 2026 | OCGN OcugenBiotechnology | SEC FORM 4 Sold | $64K57,264 at $1.12 | filing |
| 9 Sep 2026filed 11 Sep 2026 | OCGN OcugenBiotechnology | SEC FORM 4 Sold | $525K468,727 at $1.12 | filing |
| 9 Sep 2026filed 11 Sep 2026 | OCGN OcugenBiotechnology | SEC FORM 4 Sold | $64K57,264 at $1.12 | filing |
| 2 Jan 2026filed 6 Jan 2026 | OCGN OcugenBiotechnology | SEC FORM 4 Code A | —3,123,201 at $0.00 | filing |
| 2 Jan 2026filed 6 Jan 2026 | OCGN Ocugenoption or derivative · Biotechnology | SEC FORM 4 Code A | —3,123,201 at $0.00 | filing |
| 2 Jan 2026filed 6 Jan 2026 | OCGN Ocugenoption or derivative · Biotechnology | SEC FORM 4 Code A | —3,123,201 at $0.00 | filing |
| 2 Jan 2026filed 6 Jan 2026 | OCGN OcugenBiotechnology | SEC FORM 4 Code A | —3,123,201 at $0.00 | filing |
| 3 Jan 2025filed 6 Jan 2025 | OCGN OcugenBiotechnology | SEC FORM 4 Code F | $158K177,146 at $0.89 | filing |
| 2 Jan 2025filed 6 Jan 2025 | OCGN Ocugenoption or derivative · Biotechnology | SEC FORM 4 Code A | —1,827,485 at $0.00 | filing |
| 3 Jan 2024filed 5 Jan 2024 | OCGN OcugenBiotechnology | SEC FORM 4 Code F | $117K180,204 at $0.65 | filing |
| 2 Jan 2024filed 4 Jan 2024 | OCGN Ocugenoption or derivative · Biotechnology | SEC FORM 4 Code A | —492,126 at $0.00 | filing |
| 16 Feb 2023filed 17 Feb 2023 | OCGN Ocugenoption or derivative · Biotechnology | SEC FORM 4 Code M | —100,000 at $0.00 | filing |
| 16 Feb 2023filed 17 Feb 2023 | OCGN OcugenBiotechnology | SEC FORM 4 Code M | $33K100,000 at $0.33 | filing |
| 16 Feb 2023filed 17 Feb 2023 | OCGN OcugenBiotechnology | SEC FORM 4 Sold | $108K100,000 at $1.08 | filing |
| 17 Jan 2023filed 19 Jan 2023 | OCGN Ocugenoption or derivative · Biotechnology | SEC FORM 4 Code M | —100,000 at $0.00 | filing |
| 17 Jan 2023filed 19 Jan 2023 | OCGN OcugenBiotechnology | SEC FORM 4 Code M | $51K100,000 at $0.51 | filing |
| 17 Jan 2023filed 19 Jan 2023 | OCGN OcugenBiotechnology | SEC FORM 4 Sold | $128K100,000 at $1.28 | filing |
News
Ocugen (NASDAQ:OCGN) Stock: Insider Shankar Musunuri Sells 468,727 Sharestickerreport.com · 14 Oct 2026Ocugen Licenses OCU400 Gene Therapy To Roots Pharmaceutical For MENA RegionOCGN · rttnews.com · 14 Oct 2026Ocugen Expands OCU400 Gene Therapy Reach With $255 Mln Milestone DealOCGN · rttnews.com · 14 Oct 2026Ocugen and Roots Pharmaceutical Complete License Agreement for OCU400 Modifier Gene Therapy for Retinitis Pigmentosa in the Middle East and North AfricaOCGN · manilatimes.net · 14 Oct 2026
1 headline in the last 90 days name Shankar Musunuri; 3 articles from the last 14 days about the 1 company they traded most, at most three about any one of them.